1
|
Franceschini T, Giunchi F, Mollica V, Altimari A, Capizzi E, Banfi M, Schiavina R, Fiorentino M, Massari F. Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study. Diagnostics (Basel) 2021; 11:diagnostics11020184. [PMID: 33525402 PMCID: PMC7910958 DOI: 10.3390/diagnostics11020184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2020] [Revised: 01/11/2021] [Accepted: 01/24/2021] [Indexed: 11/16/2022] Open
Abstract
The occurrence of kidney oncocytic lesions with an admixed papillary component is not unusual in routine pathology practice. These neoplasms with dual morphology are classically recognized as collision tumors with variable malignant potential. Using immunohistochemistry, we investigated fluorescent in situ hybridization and next generation sequencing of the genetic and phenotypic profiles in the two components of 11 kidney tumors with colliding oncocytic and papillary features. The oncocytic component was CD117 positive, CK7 negative, and AMACR negative; the papillary component was CK7 positive, AMACR positive, and CD117 negative in all cases. Fluorescence in situ hybridization (FISH) results were inconsistent. Next generation sequencing (NGS) analysis demonstrated that the mutations identified in the two tumor components were identical and displayed an allelic frequency of approximately 50%, strongly suspicious for genetic polymorphisms. The two oncocytic and papillary tumor counterparts shared the same genetic profile and did not harbor pathogenic mutations. Clinical confirmation of the biological benign features of these tumors is required. The term collision tumor is not suitable for these neoplasms, and we propose the term oncopapillary tumor for this histological entity.
Collapse
Affiliation(s)
- Tania Franceschini
- Department of Pathology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy; (T.F.); (F.G.); (A.A.); (E.C.); (M.B.)
| | - Francesca Giunchi
- Department of Pathology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy; (T.F.); (F.G.); (A.A.); (E.C.); (M.B.)
| | - Veronica Mollica
- Department of Medical Oncology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy; (V.M.); (F.M.)
| | - Annalisa Altimari
- Department of Pathology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy; (T.F.); (F.G.); (A.A.); (E.C.); (M.B.)
| | - Elisa Capizzi
- Department of Pathology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy; (T.F.); (F.G.); (A.A.); (E.C.); (M.B.)
| | - Mattia Banfi
- Department of Pathology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy; (T.F.); (F.G.); (A.A.); (E.C.); (M.B.)
| | - Riccardo Schiavina
- Department of Urology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy;
- Department of Specialistic Diagnostic and Experimental Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
| | - Michelangelo Fiorentino
- Department of Specialistic Diagnostic and Experimental Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
- Correspondence:
| | - Francesco Massari
- Department of Medical Oncology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy; (V.M.); (F.M.)
| |
Collapse
|
2
|
Ricci C, Capizzi E, Giunchi F, Casolari L, Gelsomino F, Rihawi K, Natali F, Livi V, Trisolini R, Fiorentino M, Ardizzoni A. Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. Ther Adv Med Oncol 2020; 12:1758835920954802. [PMID: 33299472 PMCID: PMC7711224 DOI: 10.1177/1758835920954802] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Accepted: 08/12/2020] [Indexed: 12/18/2022] Open
Abstract
Introduction: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assessment is
mandatory for the single agent pembrolizumab treatment of patients with
advanced non-small cell lung cancer (NSCLC). PD-L1 testing has been
validated and is currently certified only on formalin-fixed
paraffin-embedded materials but not on cytological smears. Unfortunately, a
significant proportion of patients, having only cytological material
available, cannot be tested for PD-L1 and treated with pembrolizumab. In
this study, we aimed to validate PD-L1 IHC on cytological smears
prospectively by comparing clone SP263 staining in 150 paired histological
samples and cytological smears of NSCLC patients. Methods: We prospectively enrolled 150 consecutive advanced NSCLC patients. The clone
SP263 was selected as, in a previous study of our group, it showed higher
accuracy compared with clones 28-8 and 22-C3, with good cyto-histological
agreement using a cut-off of 50%. For cyto-histological concordance, we
calculated the kappa coefficient using two different cut-offs according to
the percentage of PD-L1 positive neoplastic cells (<1%, 1–49% and ⩾50%;
<50%, ⩾50%). Results: The overall agreement between histological samples and cytological smears was
moderate (kappa = 0.537). However, when the cyto-histological concordance
was calculated using the cut-off of 50%, the agreement was good
(kappa = 0.740). With the same cut-off, and assuming as gold-standard the
results on formalin-fixed paraffin-embedded materials, PD-L1 evaluation on
smears showed specificity and negative predictive values of 98.1% and 93.9%,
respectively. Conclusion: Cytological smears can be used in routine clinical practice for PD-L1
assessment with a cut-off of 50%, expanding the potential pool of NSCLC
patients as candidates for first-line single agent pembrolizumab
therapy.
Collapse
Affiliation(s)
| | - Elisa Capizzi
- Department of Pathology, Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy
| | - Francesca Giunchi
- Department of Pathology, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia
| | | | - Francesco Gelsomino
- Department of Medical Oncology, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Karim Rihawi
- Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy
| | - Filippo Natali
- Department of Interventional Pulmunology , Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Vanina Livi
- Unit of Interventional Pulmonology, Agostino Gemelli Hospital, Largo Agostino Gemelli, Roma, Italy
| | - Rocco Trisolini
- Unit of Interventional Pulmonology, Agostino Gemelli Hospital, Largo Agostino Gemelli, Roma, Italy
| | | | | |
Collapse
|
3
|
Franceschini T, Capizzi E, Massari F, Schiavina R, Fiorentino M, Giunchi F. Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer. Pathol Res Pract 2020; 216:153012. [PMID: 32703487 DOI: 10.1016/j.prp.2020.153012] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2020] [Revised: 05/06/2020] [Accepted: 05/10/2020] [Indexed: 11/29/2022]
Abstract
BACKGROUND HER2 is a potential target of therapy in urothelial cancer (UC). Pathological case stratification according to HER2 gene amplification or HER2 protein overexpression was critical for patients' selection in previous unsuccessful clinical trial with HER2 targeting agents. STUDY DESIGN We evaluated the HER2 overexpression by immunohistochemistry (IHC) together with the amplification of the HER2 gene with chromogenic(CISH) and fluorescent (FISH) in situ hybridization in a cohort of 61 patients covering the whole spectrum of bladder UC variants, using a tissue microarray (TMA) approach. RESULTS IHC was available in all the 61 cases while ISH in 37 and FISH in 42. At IHC, 2/61 cases (3%) were scored 3+; 2 (3%) scored 2+; 2 (3%) scored 1+; the remaining 55 (91%) scored 0. At CISH analysis 10/37 cases (27%) were amplified, 6 cases with HER2 amplification showed positive HER2 IHC (3+, 2+, 1+). Seven cases with IHC score 0 were amplified at CISH. FISH analysis revealed an amplification in 5/42 cases (12%). The total number of HER2amplified cases was different between chromogenic and fluorescent ISH with 5 cases amplified using FISH compared to 10 with CISH. CONCLUSIONS In clinical trials with HER2 targeting agents the candidate patients should be investigated not only by IHC but also by ISH, independently of the IHC results. Since also usual type UC can overexpress HER2 we recommend to extend the patients' selection to all the histotypes of bladder cancer other than the micropapillary type.
Collapse
Affiliation(s)
- Tania Franceschini
- Department of Pathology, S.Orsola and Maggiore Hospital, and Department of Specialistic Diagnostic and Experimental Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
| | - Elisa Capizzi
- Department of Pathology, S.Orsola and Maggiore Hospital, and Department of Specialistic Diagnostic and Experimental Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
| | - Francesco Massari
- Department of Oncology, S.Orsola Hospital, and Department of Specialistic Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy
| | - Riccardo Schiavina
- Department of Urology, S.Orsola Hospital, and Department of Specialistic Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy
| | - Michelangelo Fiorentino
- Department of Pathology, S.Orsola and Maggiore Hospital, and Department of Specialistic Diagnostic and Experimental Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
| | - Francesca Giunchi
- Department of Pathology, S.Orsola and Maggiore Hospital, and Department of Specialistic Diagnostic and Experimental Medicine, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
| |
Collapse
|
4
|
Giunchi F, Franceschini T, Gruppioni E, Altimari A, Capizzi E, Massari F, Schiavina R, Brunelli M, Martignoni G, Fiorentino M. Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis. Diagnostics (Basel) 2020; 10:diagnostics10020123. [PMID: 32102250 PMCID: PMC7168142 DOI: 10.3390/diagnostics10020123] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Revised: 02/21/2020] [Accepted: 02/22/2020] [Indexed: 01/13/2023] Open
Abstract
Background: Clear cell tubulo-papillary renal cell carcinoma (cctpRCC) is characterized by clear cell morphology, but differs from conventional clear cell carcinoma (ccRCC) for its indolent clinical behavior and genetic background. The differential diagnosis between the two is based on histology and immunohistochemistry (IHC). Methods: We performed a comparative case-control histological, IHC, and genetic analysis by next generation sequencing (NGS), to point out the differences in 10 cases of cctpRCC, and six controls of ccRCC with low stage and grade. Results: All 16 cases showed the IHC profile with cytokeratin 7, racemase, and carbonic anhydrase IX expected for the histological features of each tumor type. By contrast, the NGS mutation analysis that covered 207 amplicons of 50 oncogenes or tumor suppressor genes provided conflicting results. Among the 10 cctpRCC cases, eight (80%) were wild type for all of the genes in the panel, while two (20%) harbored VHL mutations typical of ccRCC. Three of the six (50%) ccRCC control cases showed expected VHL mutations; two (33%) harbored pathogenic mutations in the p53 or the CKIT genes; and one (16%) was wild type. Conclusion: We can assume that histology and ICH are not sufficient for a definitive diagnosis of cctpRCC or ccRCC. Although with a panel covering 50 genes, we found that 80% of cctpRCC were genetically silent; thus, suggesting an indolent biology of these tumors. The differential diagnosis between ccptRCC and ccRCC for the choice of the best therapeutic strategy likely requires the comprehensive evaluation of histology, IHC, and at least VHL mutations.
Collapse
Affiliation(s)
- Francesca Giunchi
- Department of Pathology, University of Bologna, 40138 Bologna, Italy; (F.G.); (T.F.); (E.G.); (A.A.); (E.C.)
| | - Tania Franceschini
- Department of Pathology, University of Bologna, 40138 Bologna, Italy; (F.G.); (T.F.); (E.G.); (A.A.); (E.C.)
| | - Elisa Gruppioni
- Department of Pathology, University of Bologna, 40138 Bologna, Italy; (F.G.); (T.F.); (E.G.); (A.A.); (E.C.)
| | - Annalisa Altimari
- Department of Pathology, University of Bologna, 40138 Bologna, Italy; (F.G.); (T.F.); (E.G.); (A.A.); (E.C.)
| | - Elisa Capizzi
- Department of Pathology, University of Bologna, 40138 Bologna, Italy; (F.G.); (T.F.); (E.G.); (A.A.); (E.C.)
| | - Francesco Massari
- Department of Oncology, University of Bologna, 40138 Bologna, Italy;
| | | | - Matteo Brunelli
- Department of Pathology, University of Verona, 37129 Verona, Italy; (M.B.); (G.M.)
| | - Guido Martignoni
- Department of Pathology, University of Verona, 37129 Verona, Italy; (M.B.); (G.M.)
| | - Michelangelo Fiorentino
- Department of Pathology, University of Bologna, 40138 Bologna, Italy; (F.G.); (T.F.); (E.G.); (A.A.); (E.C.)
- Correspondence: ; Tel.: +39-051-317-2114
| |
Collapse
|
5
|
Gatto L, Del Gaudio M, Ravaioli M, Cescon M, Tonini V, Cervellera M, Franceschelli A, Pirini MG, Di Scioscio V, Buia F, Niro F, Capizzi E, Fiorentino M, Astolfi A, Indio V, Nannini M, Pantaleo MA, Saponara M. Paratesticular Mesenchymal Malignancies: A Single-Center Case Series, Clinical Management, and Review of Literature. Integr Cancer Ther 2020; 19:1534735419900554. [PMID: 32009477 PMCID: PMC7050957 DOI: 10.1177/1534735419900554] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Background: Primary soft tissue sarcomas arising from the male urinary and genital tract are rare tumors, only accounting for 1% to 2% of all malignancies of the genitourinary tract. Clinical management of advanced disease is lacking in standardized recommendations due to the rarity of the disease. To date, complete and extensive surgery represents the only curative and standardized approach for localized disease, while the impact of retroperitoneal lymphadenectomy and adjuvant treatments on clinical outcomes are still unclear. Similarly, a standardized systemic treatment for advanced metastatic disease is still missing. Cases Presentation: Four out of 274 patients have been identified in our sarcoma population. The mean age was 54 years (range = 45-73). The histotypes showed liposarcoma in 2 cases and leiomyosarcoma in the remaining 2 cases. In all 4 cases, the disease was localized at presentation, patients underwent complete surgery, and no adjuvant treatments were done. Three cases presented a recurrence of disease at a mean follow-up of 86 months (range = 60-106 months), more than 7 years. Two cases were treated with a second surgery and chemotherapy and 1 case only with chemotherapy. Discussion and Conclusions: Sharing data about clinical management of paratesticular mesenchymal tumors is a key issue due to the rarity of this tumor's subtype. In this article, we report the clinical history of 4 patients affected by paratesticular mesenchymal tumor. In particular, main issues of interest are the decision of postoperative treatment and systemic treatment at time of disease recurrence.
Collapse
Affiliation(s)
- Lidia Gatto
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | - Massimo Del Gaudio
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | - Matteo Ravaioli
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | - Matteo Cescon
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | - Valeria Tonini
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | - Maurizio Cervellera
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | | | - Maria Giulia Pirini
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | - Valerio Di Scioscio
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | - Francesco Buia
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | - Fabio Niro
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | - Elisa Capizzi
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | | | | | | | - Margherita Nannini
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| | | | - Maristella Saponara
- Sant'Orsola-Malpighi Hospital, Bologna, Italy.,University of Bologna, Bologna, Italy
| |
Collapse
|
6
|
Facchinetti F, Bozzetti F, Gnetti L, Minari R, Crafa P, Rebuzzi SE, Ferrara R, Gruppioni E, Capizzi E, Giombelli E, Crisi G, Altimari A, Tiseo M. Wide and Cystic Brain Metastases Reveal RET-Rearranged Non-Small-Cell Lung Cancers. JCO Precis Oncol 2019; 3:1-7. [PMID: 35100707 DOI: 10.1200/po.19.00073] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Francesco Facchinetti
- University Hospital of Parma, Parma, Italy.,Université Paris Saclay, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | | | | - Marcello Tiseo
- University Hospital of Parma, Parma, Italy.,University of Parma, Parma, Italy
| |
Collapse
|
7
|
Livi V, Ardizzoni A, Cancellieri A, Natali F, Ferrari M, Paioli D, De Biase D, Capizzi E, Tallini G, Fiorentino M, Trisolini R. Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer. Clin Respir J 2019; 13:590-597. [PMID: 31343834 DOI: 10.1111/crj.13063] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2019] [Revised: 05/12/2019] [Accepted: 07/19/2019] [Indexed: 02/05/2023]
Abstract
INTRODUCTION AND OBJECTIVES Endosonography is increasingly used for the diagnosis of centrally located, bronchoscopically invisible intrapulmonary lesions, but data regarding its utility for molecular profiling are lacking. We aimed to assess the suitability of endosonography samples obtained from intrapulmonary lesions for cancer genotyping and programmed-death ligand 1 (PD-L1) testing. METHODS A prospectively collected database regarding 99 consecutive patients undergoing endosonography for the diagnosis of an intrapulmonary lesion was retrospectively reviewed. Genotyping ± PD-L1 testing was carried out in the 53 patients with advanced lung cancer and was classified as complete if all clinically indicated tests could be performed, incomplete if at least one test could not be carried out, and unsuccessful if the sample was unsuitable for molecular analysis. RESULTS All clinically indicated biomarkers could be tested in 44 (83%) patients, whereas the molecular profiling was classified as incomplete in 6 (11.3%), and unsuccessful in 3 (5.7%). Thirty-seven genetic alterations (KRAS mutation, 17; EGFR mutation, 17; ALK rearrangement, 3) and 2 cases of PD-L1 expression >50% were found in 31 (58%) patients. EGFR was successfully analysed in 94.1% of cases, KRAS in 93.9%, ALK in 89%, ROS1 in 90% and PD-L1 in 63.1%. CONCLUSION Endosonography-derived samples from intrapulmonary lesions were suitable for a thorough molecular profiling in most patients. The few cases of incomplete accomplishment of the testing algorithm were related to the failure of PD-L1 analysis due to the exhaustion of the sample or the lack of sufficient tumour cells in the paraffin-embedded material.
Collapse
Affiliation(s)
- Vanina Livi
- Interventional Pulmonology Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Andrea Ardizzoni
- Medical Oncology Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | | | - Filippo Natali
- Interventional Pulmonology Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Marco Ferrari
- Interventional Pulmonology Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Daniela Paioli
- Interventional Pulmonology Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Dario De Biase
- Molecular Diagnostic Unit, Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Elisa Capizzi
- Laboratory of Medical Oncological Pathology, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Giovanni Tallini
- Molecular Diagnostic Unit, Department of Medicine, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy
| | | | - Rocco Trisolini
- Interventional Pulmonology Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy
| |
Collapse
|
8
|
Capizzi E, Dall’Olio FG, Gruppioni E, Sperandi F, Altimari A, Giunchi F, Fiorentino M, Ardizzoni A. Clinical significance of ROS1 5’ deletions in non-small cell lung cancer. Lung Cancer 2019; 135:88-91. [DOI: 10.1016/j.lungcan.2019.07.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 06/12/2019] [Accepted: 07/17/2019] [Indexed: 12/18/2022]
|
9
|
Dall’Olio F, Lamberti G, Capizzi E, Gruppioni E, Sperandi F, Altimari A, Giunchi F, Fiorentino M, Ardizzoni A. Clinical significance of ROS1 5’ deletions detected by FISH and response to crizotinib. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Capizzi E, Ricci C, Giunchi F, Zagnoni S, Ceccarelli C, Gómez BUÁ, Casolari L, Gelsomino F, Trisolini R, Fiorentino M, Ardizzoni A. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. Lung Cancer 2018; 126:9-14. [DOI: 10.1016/j.lungcan.2018.10.017] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Revised: 10/05/2018] [Accepted: 10/15/2018] [Indexed: 01/02/2023]
|
11
|
Rihawi K, Alfieri R, Fiorentino M, Fontana F, Capizzi E, Cavazzoni A, Terracciano M, La Monica S, Ferrarini A, Buson G, Petronini PG, Ardizzoni A. MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. Transl Oncol 2018; 12:116-121. [PMID: 30290287 PMCID: PMC6171095 DOI: 10.1016/j.tranon.2018.09.013] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2018] [Revised: 09/24/2018] [Accepted: 09/24/2018] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION Translocations of the anaplastic lymphoma kinase (ALK) can be effectively targeted in advanced non-small cell lung cancer by ALK-TKI inhibitors including Crizotinib. However, the development of acquired resistance often limits the duration of these therapies. While several mechanisms of secondary resistance have been already identified, little is known about molecular determinants of primary resistance. In our brief report we investigated the tumor molecular profile of a patient who failed to respond to Crizotinib. METHODS Fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS) were run on tumor specimen as well as search and characterization of circulating tumor cells (CTCs) in the blood. Confirmation of clinical findings was achieved using a translational cell-line in vitro model. RESULTS We identified the amplification of MYC as a potential new mechanism of primary resistance to ALK inhibition. Human EML4-ALK rearranged cells infected with a lentiviral vector carrying full-length human MYC cDNA were treated in vitro with crizotinib and alectinib. Overexpression of MYC overexpression was associated with a reduced sensitivity to both ALK-inhibitors. MYC-overexpressing clones displayed also increased levels of both cyclin D and E and their growth was reduced by using Cdk4/6 inhibitors such as Palbociclib. CONCLUSIONS We postulate that the MYC gene may be implicated in the mechanism of primary resistance to ALK inhibitors. We also suggest potential MYC-directed inhibition strategies to overcome primary resistance in advanced ALK-rearranged NSCLC.
Collapse
Affiliation(s)
- Karim Rihawi
- Department of Experimental, Diagnostic and Specialty Medicine DIMES - University of Bologna, Via Massarenti 9, 40138, Bologna, Italy; Medical Oncology, S.Orsola-Malpighi University Hospital and Alma Mater University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
| | - Roberta Alfieri
- Experimental Oncology Laboratory, Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126, Italy
| | - Michelangelo Fiorentino
- Department of Experimental, Diagnostic and Specialty Medicine DIMES - University of Bologna, Via Massarenti 9, 40138, Bologna, Italy; Molecular Pathology, S.Orsola-Malpighi University Hospital and Alma Mater University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
| | - Francesca Fontana
- Menarini Silicon Biosystems SpA, Via Giuseppe di Vittorio 21, 40013, Castel Maggiore, Italy
| | - Elisa Capizzi
- Department of Experimental, Diagnostic and Specialty Medicine DIMES - University of Bologna, Via Massarenti 9, 40138, Bologna, Italy; Molecular Pathology, S.Orsola-Malpighi University Hospital and Alma Mater University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
| | - Andrea Cavazzoni
- Experimental Oncology Laboratory, Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126, Italy
| | - Mario Terracciano
- Menarini Silicon Biosystems SpA, Via Giuseppe di Vittorio 21, 40013, Castel Maggiore, Italy
| | - Silvia La Monica
- Experimental Oncology Laboratory, Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126, Italy
| | - Alberto Ferrarini
- Menarini Silicon Biosystems SpA, Via Giuseppe di Vittorio 21, 40013, Castel Maggiore, Italy
| | - Genny Buson
- Menarini Silicon Biosystems SpA, Via Giuseppe di Vittorio 21, 40013, Castel Maggiore, Italy
| | - Pier Giorgio Petronini
- Experimental Oncology Laboratory, Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126, Italy
| | - Andrea Ardizzoni
- Department of Experimental, Diagnostic and Specialty Medicine DIMES - University of Bologna, Via Massarenti 9, 40138, Bologna, Italy; Medical Oncology, S.Orsola-Malpighi University Hospital and Alma Mater University of Bologna, Via Massarenti 9, 40138, Bologna, Italy
| |
Collapse
|
12
|
Zuntini R, Cortesi L, Calistri D, Pippucci T, Martelli PL, Casadio R, Capizzi E, Santini D, Miccoli S, Medici V, Danesi R, Marchi I, Zampiga V, Fiorentino M, Ferrari S, Turchetti D. BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. Oncotarget 2017; 8:22640-22648. [PMID: 28186987 PMCID: PMC5410251 DOI: 10.18632/oncotarget.15151] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Accepted: 01/26/2017] [Indexed: 11/25/2022] Open
Abstract
We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from the Emilia-Romagna region of Italy, including 20 breast and 23 ovarian cancer cases; four families displayed site-specific ovarian cancer. The variant, absent in human variation databases, has been reported three times in BRCA1 specific databases; all probands shared the same rare haplotype at the BRCA1 locus, consistent with a common ancestor. The multifactorial likelihood method by Goldgar, used to estimate the probability of the variant being causative, gave a ratio of 2,263,474:1 in favor of causality. Moreover, in silico modeling suggested that His1673-lacking BRCA1 protein may have a decreased ability to bind BARD1 and other related proteins. All six ovarian carcinomas and two out of four breast carcinomas available showed a loss of the BRCA1 wild-type allele, which in three out of four ovarian carcinomas analyzed by FISH was associated with duplication of the chromosome 17 containing the variant. Although the pathogenicity of the allele is strongly supported by the multifactorial ratio, we cannot exclude that p.His1673del is not itself deleterious, but is linked to another undetected mutation on the same ancestral allele.
Collapse
Affiliation(s)
- Roberta Zuntini
- Dipartimento di Scienze Mediche e Chirurgiche, Centro di Ricerca sui Tumori Ereditari, UO Genetica Medica, Università di Bologna, Bologna, Italy
| | - Laura Cortesi
- Dipartimento di Oncologia ed Ematologia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy
| | - Daniele Calistri
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Tommaso Pippucci
- Dipartimento di Scienze Mediche e Chirurgiche, Centro di Ricerca sui Tumori Ereditari, UO Genetica Medica, Università di Bologna, Bologna, Italy
| | - Pier Luigi Martelli
- Biocomputing Group, BIGEA/Giorgio Prodi Interdepartmental Center for Cancer Research, Università di Bologna, Bologna, Italy
| | - Rita Casadio
- Biocomputing Group, BIGEA/Giorgio Prodi Interdepartmental Center for Cancer Research, Università di Bologna, Bologna, Italy
| | - Elisa Capizzi
- UO Anatomia Patologica, Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - Donatella Santini
- UO Anatomia Patologica, Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - Sara Miccoli
- Dipartimento di Scienze Mediche e Chirurgiche, Centro di Ricerca sui Tumori Ereditari, UO Genetica Medica, Università di Bologna, Bologna, Italy
| | - Veronica Medici
- Dipartimento di Oncologia ed Ematologia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy
| | - Rita Danesi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Isabella Marchi
- Dipartimento di Oncologia ed Ematologia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy
| | - Valentina Zampiga
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Michelangelo Fiorentino
- UO Anatomia Patologica, Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy
| | - Simona Ferrari
- Dipartimento di Scienze Mediche e Chirurgiche, Centro di Ricerca sui Tumori Ereditari, UO Genetica Medica, Università di Bologna, Bologna, Italy
| | - Daniela Turchetti
- Dipartimento di Scienze Mediche e Chirurgiche, Centro di Ricerca sui Tumori Ereditari, UO Genetica Medica, Università di Bologna, Bologna, Italy
| |
Collapse
|
13
|
Dika E, Fanti PA, Fiorentino M, Capizzi E, Neri I, Piraccini BM, Ravaioli GM, Misciali C, Passarini B, Patrizi A. Spitzoid tumors in children and adults. Melanoma Res 2015; 25:295-301. [DOI: 10.1097/cmr.0000000000000160] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
14
|
Bellavista E, Martucci M, Vasuri F, Santoro A, Mishto M, Kloss A, Capizzi E, Degiovanni A, Lanzarini C, Remondini D, Dazzi A, Pellegrini S, Cescon M, Capri M, Salvioli S, D'Errico-Grigioni A, Dahlmann B, Grazi GL, Franceschi C. Lifelong maintenance of composition, function and cellular/subcellular distribution of proteasomes in human liver. Mech Ageing Dev 2014; 141-142:26-34. [PMID: 25265087 DOI: 10.1016/j.mad.2014.09.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2014] [Revised: 09/18/2014] [Accepted: 09/19/2014] [Indexed: 11/29/2022]
Abstract
Owing to organ shortage, livers from old donors are increasingly used for transplantation. The function and duration of such transplanted livers are apparently comparable to those from young donors, suggesting that, despite some morphological and structural age-related changes, no major functional changes do occur in liver with age. We tested this hypothesis by performing a comprehensive study on proteasomes, major cell organelles responsible for proteostasis, in liver biopsies from heart-beating donors. Oxidized and poly-ubiquitin conjugated proteins did not accumulate with age and the three major proteasome proteolytic activities were similar in livers from young and old donors. Analysis of proteasomes composition showed an age-related increased of β5i/α4 ratio, suggesting a shift toward proteasomes containing inducible subunits and a decreased content of PA28α subunit, mainly in the cytosol of hepatocytes. Thus our data suggest that, proteasomes activity is well preserved in livers from aged donors, concomitantly with subtle changes in proteasome subunit composition which might reflect the occurrence of a functional remodelling to maintain an efficient proteostasis. Gender differences are emerging and they deserve further investigations owing to the different aging trajectories between men and women. Finally, our data support the safe use of livers from old donors for transplantation.
Collapse
Affiliation(s)
- Elena Bellavista
- Interdepartmental Centre "L. Galvani" for Integrated Studies on Biophysics, Bioinformatics and Biocomplexity (CIG), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
| | - Morena Martucci
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
| | - Francesco Vasuri
- "F. Addarii" Institute of Oncology and Transplant Pathology at Department of Experimental, Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi Hospital, 40138 Bologna, Italy.
| | - Aurelia Santoro
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
| | - Michele Mishto
- Institute of Biochemistry, Charité Universitaetsmedizin Berlin, 10117 Berlin, Germany; Centro Interdipartimentale di Ricerca sul Cancro "Giorgio Prodi" (CIRC), University of Bologna, 40126 Bologna, Italy.
| | - Alexander Kloss
- Institute of Biochemistry, Charité Universitaetsmedizin Berlin, 10117 Berlin, Germany.
| | - Elisa Capizzi
- "F. Addarii" Institute of Oncology and Transplant Pathology at Department of Experimental, Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi Hospital, 40138 Bologna, Italy.
| | - Alessio Degiovanni
- "F. Addarii" Institute of Oncology and Transplant Pathology at Department of Experimental, Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi Hospital, 40138 Bologna, Italy.
| | - Catia Lanzarini
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
| | - Daniel Remondini
- Interdepartmental Centre "L. Galvani" for Integrated Studies on Biophysics, Bioinformatics and Biocomplexity (CIG), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy; Department of Physics and Astronomy (DIFA) and INFN Sez. Bologna, Alma Mater Studiorum, University of Bologna, 40127 Bologna, Italy.
| | - Alessandro Dazzi
- Department of General Surgery and Organ Transplantation, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy.
| | - Sara Pellegrini
- Department of General Surgery and Organ Transplantation, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy.
| | - Matteo Cescon
- Department of General Surgery and Organ Transplantation, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy.
| | - Miriam Capri
- Interdepartmental Centre "L. Galvani" for Integrated Studies on Biophysics, Bioinformatics and Biocomplexity (CIG), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
| | - Stefano Salvioli
- Interdepartmental Centre "L. Galvani" for Integrated Studies on Biophysics, Bioinformatics and Biocomplexity (CIG), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
| | - Antonia D'Errico-Grigioni
- "F. Addarii" Institute of Oncology and Transplant Pathology at Department of Experimental, Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi Hospital, 40138 Bologna, Italy.
| | - Burkhardt Dahlmann
- Institute of Biochemistry, Charité Universitaetsmedizin Berlin, 10117 Berlin, Germany.
| | | | - Claudio Franceschi
- Interdepartmental Centre "L. Galvani" for Integrated Studies on Biophysics, Bioinformatics and Biocomplexity (CIG), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy; IRCCS Institute of Neurological Sciences, 40139 Bologna, Italy; National Research Council of Italy, CNR, Institute for Organic Synthesis and Photoreactivity (ISOF), 40129 Bologna, Italy; National Research Council of Italy, CNR, Institute of Molecular Genetics, Unit of Bologna IOR, 40136 Italy.
| |
Collapse
|
15
|
Gohlke S, Mishto M, Textoris-Taube K, Keller C, Giannini C, Vasuri F, Capizzi E, D’Errico-Grigioni A, Kloetzel PM, Dahlmann B. Molecular alterations in proteasomes of rat liver during aging result in altered proteolytic activities. Age (Dordr) 2014; 36:57-72. [PMID: 23690132 PMCID: PMC3889881 DOI: 10.1007/s11357-013-9543-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2012] [Accepted: 05/08/2013] [Indexed: 06/02/2023]
Abstract
Aging induces alterations of tissue protein homoeostasis. To investigate one of the major systems catalysing intracellular protein degradation we have purified 20S proteasomes from rat liver of young (2 months) and aged (23 months) animals and separated them into three subpopulations containing different types of intermediate proteasomes with standard- and immuno-subunits. The smallest subpopulation ΙΙΙ and the major subpopulation Ι comprised proteasomes containing immuno-subunits β1i and β5i beside small amounts of standard-subunits, whereas proteasomes of subpopulation ΙΙ contained only β5i beside standard-subunits. In favour of a relative increase of the major subpopulation Ι, subpopulation ΙΙ and ΙΙΙ were reduced for about 55 % and 80 %, respectively, in aged rats. Furthermore, in all three 20S proteasome subpopulations from aged animals standard-active site subunits were replaced by immuno-subunits. Overall, this transformation resulted in a relative increase of immuno-subunit-containing proteasomes, paralleled by reduced activity towards short fluorogenic peptide substrates. However, depending on the substrate their hydrolysing activity of long polypeptide substrates was significantly higher or unchanged. Furthermore, our data revealed an altered MHC class I antigen-processing efficiency of 20S proteasomes from liver of aged rats. We therefore suggest that the age-related intramolecular alteration of hepatic proteasomes modifies its cleavage preferences without a general decrease of its activity. Such modifications could have implications on protein homeostasis as well as on MHC class I antigen presentation as part of the immunosenescence process.
Collapse
Affiliation(s)
- Sabrina Gohlke
- />Institute of Biochemistry, Charité-Universitätsmedizin Berlin, CCM, CharitéCrossOver, Charitéplatz 1, 10117 Berlin, Germany
| | - Michele Mishto
- />Institute of Biochemistry, Charité-Universitätsmedizin Berlin, CCM, CharitéCrossOver, Charitéplatz 1, 10117 Berlin, Germany
- />Centro Interdipartimentale di Ricerca sul Cancro “Giorgio Prodi”, University of Bologna, Bologna, Italy
| | - Kathrin Textoris-Taube
- />Institute of Biochemistry, Charité-Universitätsmedizin Berlin, CCM, CharitéCrossOver, Charitéplatz 1, 10117 Berlin, Germany
| | - Christin Keller
- />Institute of Biochemistry, Charité-Universitätsmedizin Berlin, CCM, CharitéCrossOver, Charitéplatz 1, 10117 Berlin, Germany
| | - Carolin Giannini
- />Institute of Biochemistry, Charité-Universitätsmedizin Berlin, CCM, CharitéCrossOver, Charitéplatz 1, 10117 Berlin, Germany
| | - Francesco Vasuri
- />“F. Addarii” Institute of Oncology and Transplant Pathology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Elisa Capizzi
- />“F. Addarii” Institute of Oncology and Transplant Pathology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Antonia D’Errico-Grigioni
- />“F. Addarii” Institute of Oncology and Transplant Pathology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Peter-Michael Kloetzel
- />Institute of Biochemistry, Charité-Universitätsmedizin Berlin, CCM, CharitéCrossOver, Charitéplatz 1, 10117 Berlin, Germany
| | - Burkhardt Dahlmann
- />Institute of Biochemistry, Charité-Universitätsmedizin Berlin, CCM, CharitéCrossOver, Charitéplatz 1, 10117 Berlin, Germany
| |
Collapse
|
16
|
Storci G, Bertoni S, De Carolis S, Papi A, Nati M, Ceccarelli C, Pirazzini C, Garagnani P, Ferrarini A, Buson G, Delledonne M, Fiorentino M, Capizzi E, Gruppioni E, Taffurelli M, Santini D, Franceschi C, Bandini G, Bonifazi F, Bonafé M. Slug/β-catenin-dependent proinflammatory phenotype in hypoxic breast cancer stem cells. Am J Pathol 2013; 183:1688-1697. [PMID: 24036252 DOI: 10.1016/j.ajpath.2013.07.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Revised: 06/16/2013] [Accepted: 07/30/2013] [Indexed: 11/26/2022]
Abstract
Cancer stem cell survival relies on the activation of inflammatory pathways, which is speculatively triggered by cell autonomous mechanisms or by microenvironmental stimuli. Here, we observed that hypoxic bone marrow stroma-derived transforming growth factor-β 1 promotes the growth of human breast cancer stem cells as mammospheres. The ensuing Slug-dependent serine 139 phosphorylation of the DNA damage sensor H2AX in breast cancer stem cells induces tumor necrosis factor-α and IL-8 mRNAs, whose stability is enhanced by cytoplasmic β-catenin. β-Catenin also up-regulates and binds miR-221, reducing the stability of the miR-221 targets Rad51 and ERα mRNAs. Our data show that the Slug/β-catenin-dependent activation of DNA damage signaling triggered by the hypoxic microenvironment sustains the proinflammatory phenotype of breast cancer stem cells.
Collapse
Affiliation(s)
- Gianluca Storci
- Department of Experimental, Diagnostic and Specialty Medicine, St. Orsola-Malpighi University Hospital, Bologna, Italy; Center for Applied Biomedical Research, St. Orsola-Malpighi University Hospital, Bologna, Italy.
| | - Sara Bertoni
- Center for Applied Biomedical Research, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Sabrina De Carolis
- Department of Experimental, Diagnostic and Specialty Medicine, St. Orsola-Malpighi University Hospital, Bologna, Italy; Center for Applied Biomedical Research, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Alessio Papi
- Department of Biological, Geological and Environmental Sciences, Functional Genomics Center, University of Verona, Verona, Italy
| | - Marina Nati
- Department of Experimental, Diagnostic and Specialty Medicine, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Claudio Ceccarelli
- Department of Experimental, Diagnostic and Specialty Medicine, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Chiara Pirazzini
- Department of Experimental, Diagnostic and Specialty Medicine, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Paolo Garagnani
- Department of Experimental, Diagnostic and Specialty Medicine, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Alberto Ferrarini
- Department of Biotechnologies, Functional Genomics Center, University of Verona, Verona, Italy
| | - Genny Buson
- Department of Biotechnologies, Functional Genomics Center, University of Verona, Verona, Italy
| | - Massimo Delledonne
- Department of Biotechnologies, Functional Genomics Center, University of Verona, Verona, Italy
| | - Michelangelo Fiorentino
- Pathology Unit, Addarii Institute of Oncology, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Elisa Capizzi
- Pathology Unit, Addarii Institute of Oncology, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Elisa Gruppioni
- Pathology Unit, Addarii Institute of Oncology, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Mario Taffurelli
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - Donatella Santini
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - Claudio Franceschi
- Department of Experimental, Diagnostic and Specialty Medicine, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Giuseppe Bandini
- Institute of Haematology "L & A Seragnoli", St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Francesca Bonifazi
- Institute of Haematology "L & A Seragnoli", St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Massimiliano Bonafé
- Department of Experimental, Diagnostic and Specialty Medicine, St. Orsola-Malpighi University Hospital, Bologna, Italy; Center for Applied Biomedical Research, St. Orsola-Malpighi University Hospital, Bologna, Italy.
| |
Collapse
|
17
|
Altimari A, de Biase D, De Maglio G, Gruppioni E, Capizzi E, Degiovanni A, D’Errico A, Pession A, Pizzolitto S, Fiorentino M, Tallini G. 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. Onco Targets Ther 2013; 6:1057-64. [PMID: 23950653 PMCID: PMC3741083 DOI: 10.2147/ott.s42369] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Detection of KRAS mutations in archival pathology samples is critical for therapeutic appropriateness of anti-EGFR monoclonal antibodies in colorectal cancer. We compared the sensitivity, specificity, and accuracy of Sanger sequencing, ARMS-Scorpion (TheraScreen®) real-time polymerase chain reaction (PCR), pyrosequencing, chip array hybridization, and 454 next-generation sequencing to assess KRAS codon 12 and 13 mutations in 60 nonconsecutive selected cases of colorectal cancer. Twenty of the 60 cases were detected as wild-type KRAS by all methods with 100% specificity. Among the 40 mutated cases, 13 were discrepant with at least one method. The sensitivity was 85%, 90%, 93%, and 92%, and the accuracy was 90%, 93%, 95%, and 95% for Sanger sequencing, TheraScreen real-time PCR, pyrosequencing, and chip array hybridization, respectively. The main limitation of Sanger sequencing was its low analytical sensitivity, whereas TheraScreen real-time PCR, pyrosequencing, and chip array hybridization showed higher sensitivity but suffered from the limitations of predesigned assays. Concordance between the methods was k = 0.79 for Sanger sequencing and k > 0.85 for the other techniques. Tumor cell enrichment correlated significantly with the abundance of KRAS-mutated deoxyribonucleic acid (DNA), evaluated as ΔCt for TheraScreen real-time PCR (P = 0.03), percentage of mutation for pyrosequencing (P = 0.001), ratio for chip array hybridization (P = 0.003), and percentage of mutation for 454 next-generation sequencing (P = 0.004). Also, 454 next-generation sequencing showed the best cross correlation for quantification of mutation abundance compared with all the other methods (P < 0.001). Our comparison showed the superiority of next-generation sequencing over the other techniques in terms of sensitivity and specificity. Next-generation sequencing will replace Sanger sequencing as the reference technique for diagnostic detection of KRAS mutation in archival tumor tissues.
Collapse
Affiliation(s)
- Annalisa Altimari
- Laboratory of Molecular Oncologic and Transplantation Pathology, S. Orsola-Malpighi Hospital, Bologna, Italy
| | - Dario de Biase
- Laboratory of Molecular Pathology, Anatomic Pathology, Bellaria Hospital, Bologna, Italy
| | - Giovanna De Maglio
- Department of Pathology, S. Maria della Misericordia Hospital, Udine, Italy
| | - Elisa Gruppioni
- Laboratory of Molecular Oncologic and Transplantation Pathology, S. Orsola-Malpighi Hospital, Bologna, Italy
| | - Elisa Capizzi
- Laboratory of Molecular Oncologic and Transplantation Pathology, S. Orsola-Malpighi Hospital, Bologna, Italy
| | - Alessio Degiovanni
- Laboratory of Molecular Oncologic and Transplantation Pathology, S. Orsola-Malpighi Hospital, Bologna, Italy
| | - Antonia D’Errico
- Laboratory of Molecular Oncologic and Transplantation Pathology, S. Orsola-Malpighi Hospital, Bologna, Italy
| | - Annalisa Pession
- Laboratory of Molecular Pathology, Anatomic Pathology, Bellaria Hospital, Bologna, Italy
| | - Stefano Pizzolitto
- Department of Pathology, S. Maria della Misericordia Hospital, Udine, Italy
| | - Michelangelo Fiorentino
- Laboratory of Molecular Oncologic and Transplantation Pathology, S. Orsola-Malpighi Hospital, Bologna, Italy
- Correspondence: Michelangelo Fiorentino, Istituto Oncologico Addarii, Viale Ercolani 4/2, 40138, Bologna, Italy, Tel +39 05 1636 3781, Fax +39 05 1636 3782, Email
| | - Giovanni Tallini
- Laboratory of Molecular Pathology, Anatomic Pathology, Bellaria Hospital, Bologna, Italy
| |
Collapse
|
18
|
Vasuri F, Capizzi E, Bellavista E, Mishto M, Santoro A, Fiorentino M, Capri M, Cescon M, Grazi GL, Grigioni WF, D’Errico-Grigioni A, Franceschi C. Studies on immunoproteasome in human liver. Part I: Absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis. Biochem Biophys Res Commun 2010; 397:301-6. [DOI: 10.1016/j.bbrc.2010.05.104] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2010] [Accepted: 05/21/2010] [Indexed: 11/12/2022]
|
19
|
Abstract
The prevalence of prostate cancer (PCa) is high and increases with age. PCa is the most common cutaneous cancer in American men. Prostate-specific antigen (PSA) screening has impacted the detection of PCa and is directly responsible for a dramatic decrease in stage at diagnosis. Gleason score and stage at the time of diagnosis remain the mainstay to predict prognosis, in the absence of more accurate and reliable tissue or blood biomarkers. Despite extensive research efforts, very few biomarkers of PCa have been introduced to date in clinical practice. Even screening with PSA has recently been questioned. A thorough analysis of all tissue and serum biomarkers in prostate cancer research cannot be easily synthesized, and goes beyond the scope of the present article. Therefore the authors focus here on the most recently reported tissue and circulating biomarkers for PCa whose application in clinical practice is either current or expected in the near future.
Collapse
Affiliation(s)
- Michelangelo Fiorentino
- Department of Pathology and Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, D1536, 44 Binney Street, Boston, MA 02115, USA
| | | | | |
Collapse
|
20
|
Zamagni C, Wirtz RM, De Iaco P, Rosati M, Veltrup E, Rosati F, Capizzi E, Cacciari N, Alboni C, Bernardi A, Massari F, Quercia S, D'Errico Grigioni A, Dietel M, Sehouli J, Denkert C, Martoni AA. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. Endocr Relat Cancer 2009; 16:1241-9. [PMID: 19749010 DOI: 10.1677/erc-08-0342] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Oestrogen receptors (ESRs) regulate the growth and differentiation of normal ovarian epithelia. However, to date their role as biomarkers in the clinical setting of ovarian cancer remains unclear. In view of potential endocrine treatment options, we tested the role of ESR1 mRNA expression in ovarian cancer in the context of a neo-adjuvant chemotherapy trial. Study participants had epithelial ovarian or peritoneal carcinoma unsuitable for optimal upfront surgery and were treated with neo-adjuvant platinum-based chemotherapy before surgery. RNA was isolated from frozen tumour biopsies before treatment. RNA expression of ESR1 was determined by microarray and reverse transcriptase kinetic PCR technologies. The prognostic value of ESR1 was tested using univariate and multivariate Cox proportional hazards models, Kaplan-Meier survival statistics and the log-rank test. ESR1 positively correlates with proliferation markers and histopathological grading. ESR1 was a significant predictor of survival as a continuous variable in the univariate Cox regression analysis. In multivariate analysis, elevated baseline ESR1 mRNA levels predicted prolonged progression-free survival (P=0.041) and overall survival (P=0.01) after neo-adjuvant chemotherapy, independently of pathological grade and age. We conclude that pretreatment ESR1 mRNA is associated with tumour growth and is a strong prognostic factor in ovarian cancer, independent of the strongest clinical parameters used in clinical routine. We suggest that ESR1 mRNA status should be considered in order to minimize possible confounding effects in ovarian cancer clinical trials, and that early treatment with anti-hormonal agents based on reliable hormone receptor status determination is worth investigating.
Collapse
MESH Headings
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Carboplatin/administration & dosage
- Carcinoma, Papillary/drug therapy
- Carcinoma, Papillary/genetics
- Carcinoma, Papillary/secondary
- Chemotherapy, Adjuvant
- Cystadenocarcinoma, Serous/drug therapy
- Cystadenocarcinoma, Serous/genetics
- Cystadenocarcinoma, Serous/secondary
- Estrogen Receptor alpha/genetics
- Female
- Gene Expression Profiling
- Humans
- Middle Aged
- Oligonucleotide Array Sequence Analysis
- Ovarian Neoplasms/drug therapy
- Ovarian Neoplasms/genetics
- Ovarian Neoplasms/pathology
- Paclitaxel/administration & dosage
- Peritoneal Neoplasms/drug therapy
- Peritoneal Neoplasms/genetics
- Peritoneal Neoplasms/secondary
- Prognosis
- RNA, Messenger/genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Survival Rate
Collapse
Affiliation(s)
- Claudio Zamagni
- Medical Oncology Unit, Policlinico S.Orsola-Malpighi Hospital, Bologna, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Altimari A, Quercia S, Benedettini E, Rosati M, Capizzi E, Bernardi A, Fiorentino M, Zamagni C, D'Errico Grigioni A, Martoni AA. Relevance of circulating tumor cells (CTC) in the progression of metastatic breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
21066 Background: metastatic breast cancer is an incurable disease. Molecular tumor staging methods are required for a better therapeutic approach. Patients and Methods: eight mL blood samples were drawn from 20 patients (pts) (mean age 61.9±9) with metastatic breast cancer at the time of the beginning of a new chemo- or hormonal treatment line. Median follow-up was 7±4.5 months. Twenty- five female healthy blood donor volunteers were used as controls. Blood samples were screened for the presence of circulating tumor cells (CTC) with a quantitative PCR method using molecular probes for human mammaglobin (hMAM) and cytokeratin 19 (CK19). Relative quantification of hMAM and CK19 RNA was obtained using a blood sample infected with known concentrations of MDA-MB453 cells as calibrator. Results: none of the healthy controls was hMAM positive while the cut-off for CK19 was calculated as the mean value of the controls plus two standard deviations. Nine of 20 (45%) pts were hMAM positive, 15/20 (75%) CK19 positive, while 18/20 (90%) pts were positive for at least one marker (CTC positive). Among the 14 (70%) pts who had a disease progression 7 died. Seven of 9 hMAM positive (78%) and 11/15 (73%) CK19 positive pts had disease progression. All the 14 pts who had disease progression were CTC positive while the only 2 CTC negative pts were free from progression at the time of last follow-up. Conclusions: (1) Multiple (hMAM, CK19) rather than single marker detection should be preferred for CTC blood screening in breast cancer. (2) Combined hMAM and CK19 evaluation might identify pts at higher risk of tumor progression and might be useful for stratification and decision making in metastatic breast cancer pts. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Altimari
- University Pathology Unit, Bologna, Italy; Medical Oncology Unit S.Orsola-Malpighi Hospital, Bologna, Italy
| | - S. Quercia
- University Pathology Unit, Bologna, Italy; Medical Oncology Unit S.Orsola-Malpighi Hospital, Bologna, Italy
| | - E. Benedettini
- University Pathology Unit, Bologna, Italy; Medical Oncology Unit S.Orsola-Malpighi Hospital, Bologna, Italy
| | - M. Rosati
- University Pathology Unit, Bologna, Italy; Medical Oncology Unit S.Orsola-Malpighi Hospital, Bologna, Italy
| | - E. Capizzi
- University Pathology Unit, Bologna, Italy; Medical Oncology Unit S.Orsola-Malpighi Hospital, Bologna, Italy
| | - A. Bernardi
- University Pathology Unit, Bologna, Italy; Medical Oncology Unit S.Orsola-Malpighi Hospital, Bologna, Italy
| | - M. Fiorentino
- University Pathology Unit, Bologna, Italy; Medical Oncology Unit S.Orsola-Malpighi Hospital, Bologna, Italy
| | - C. Zamagni
- University Pathology Unit, Bologna, Italy; Medical Oncology Unit S.Orsola-Malpighi Hospital, Bologna, Italy
| | - A. D'Errico Grigioni
- University Pathology Unit, Bologna, Italy; Medical Oncology Unit S.Orsola-Malpighi Hospital, Bologna, Italy
| | - A. A. Martoni
- University Pathology Unit, Bologna, Italy; Medical Oncology Unit S.Orsola-Malpighi Hospital, Bologna, Italy
| |
Collapse
|